



Under the Paperwork Reduction Act

95. no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

		Application Number	10/773,618
		Filing Date	February 6, 2004
		First Named Inventor	Thomas W. DUBENSKY, Jr.
		Art Unit	1645
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	16 + 73 Refs.	Attorney Docket Number	282172002800

ENCLOSURES (Check all that apply)


<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	1. Form PTO-1449 + copy (12 pages) 2. 73 References 3. Return Receipt Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement (Supplemental – 3 pages)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<input type="checkbox"/> Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	MORRISON & FOERSTER LLP (Customer No. 25226)		
Signature			
Printed name	Alicia J. Hager	Reg. No.	44,140
Date	January 6, 2005		

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV336621631US, in a box addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: January 6, 2005

Signature:  (Georgina Matos)



1-10-05


5/5/05

PATENT
Docket No. 282172002800

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV336621631US, in a box addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: January 6, 2005

Signature: 

(Georgina Matos)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Thomas W. DUBENSKY, Jr. et al.

Serial No.: 10/773,618

Filing Date: February 6, 2004

For: MODIFIED FREE-LIVING MICROBES,
VACCINE COMPOSITIONS AND
METHODS OF USE THEREOF

Examiner: Not Yet Assigned

Group Art Unit: 1645

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record in the application.

This Supplemental Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of __ is enclosed.
 - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **282172002800**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.


Dated: January 6, 2005

Respectfully submitted,


By _____
Alicia J. Hager
Registration No. 44,140

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-4296
Facsimile: (650) 494-0792

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 282172002800	Application Number 10/773,618
		Applicant	Thomas W. DUBENSKY, Jr. et al.
		Filing Date February 6, 2004	Group Art Unit 1645
		Mailing Date January 6, 2005	



U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	03/07/2002	2002/0028432	Cook et al.			
	2.	12/05/2002	2002/0182581	Cook et al.			
	3.	09/16/2004	2004/0180321	Cook et al.			
	4.	11/18/2004	2004/0228877	Dubensky, JR et al.			
	5.	01/09/2001	6,171,777	Cook et al.			
	6.	01/23/2001	6,177,441	Cook et al.			
	7.	06/25/2002	6,410,219	Cook et al.			
	8.	01/27/2004	6,682,729	Powell et al.			
	9.	03/23/2004	6,709,810	Cook et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	10.	08/06/1993	FR 2 686 896	France			Abstract
	11.	08/05/1993	WO 93/15212	WIPO			YES
	12.	11/07/1996	WO 96/34631	WIPO			
	13.	12/19/1996	WO 96/39818	WIPO			
	14.	06/17/1999	WO 99/29884	WIPO			
	15.	07/15/2000	WO 99/34839	WIPO			
	16.	10/17/2002	WO 02/20982	WIPO			
	17.	10/07/2004	WO 04/084936	WIPO			
	18.	12/23/2004	WO 04/110481	WIPO			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 282172002800	Application Number 10/773,618
		Applicant	Thomas W. DUBENSKY, Jr. et al.
		Filing Date February 6, 2004	Group Art Unit 1645
		Mailing Date January 6, 2005	

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	19.	Barry, R.A. et al. (April 1992). "Pathogenicity and Immunogenicity of <i>Listeria monocytogenes</i> Small-Plaque Mutants Defective for Intracellular Growth and Cell-to-Cell Spread," <i>Infection and Immunity</i> 60(4):1625-1632.
	20.	Bast, R.C. et al. (March 1975). "Antitumor Activity of Bacterial Infection. I. Effect of <i>Listeria monocytogenes</i> on Growth of a Murine Fibrosarcoma," <i>Journal of the National Cancer Institute</i> 54(3):749-756.
	21.	Bast, R.C. et al. (March 1975). "Antitumor Activity of Bacterial Infection. II. Effect of <i>Listeria monocytogenes</i> on Growth of a Guinea Pig Hepatoma," <i>Journal of the National Cancer Institute</i> 54(3):757-761.
	22.	Bergmann, B. et al. (February 2002). "InlA- but not InlB-mediated Internalization of <i>Listeria monocytogenes</i> by Non-Phagocytic Mammalian Cells Needs the Support of Other Internalins," <i>Molecular Microbiology</i> 43(3):557-570.
	23.	Boon, T. et al. (1994). "Tumor Antigens Recognized by T Lymphocytes," <i>Annu. Rev. Immunol.</i> 12:337-365.
	24.	Bouwer, H.G.A. et al. (April 14, 2003). "Recombinant L. monocytogenes as a Vaccine For Stimulation of Anti-Tumor Responses," (Abstract for the 90th Anniversary Meeting of the American Association of Immunologists, Denver, CO May 6 -10, 2003) <i>FASEB Journal</i> , 17(7):C330-331, Abstract 162.17.
	25.	Braun, L. et al. (October 1999). "The 213-amino-acid Leucine-rich Repeat Region of the <i>Listeria monocytogenes</i> InIB Protein is Sufficient for Entry into Mammalian Cells, Stimulation of PI 3-Kinase and Membrane Ruffling," <i>Molecular Microbiology</i> 34(1):10-23.
	26.	Bridges, B.A. et al. (August 1979). "Inactivation of <i>Escherichia coli</i> by Near-Ultraviolet Light and 8-Methoxysoralen: Different Responses of Strains B/r and K-12," <i>Journal of Bacteriology</i> 139(2):454-459.
	27.	Brockstedt, D. et al. (July 2003). "Recombinant Attenuated <i>Listeria monocytogenes</i> Elicits Robust Cellular Immune Response to Tumor-Associated Antigen in <i>Listeria</i> Immune Mice," (Abstract for the 94th Annual Meeting of the American Association for Cancer Research, Washington DC, USA, July 11-14, 2003) <i>Proceedings of the American Association For Cancer Research Annual Meeting</i> 44(2):168, Abstract No. 851.
	28.	Brockstedt, D.G. et al. (September 21, 2004). "Listeria-based Cancer Vaccines That Segregate Immunogenicity From Toxicity," <i>Proc. Natl. Acad. Sci. USA</i> Vol. 101(38):13832-13837.
	29.	Brooks, P.C. et al. (August 2001). "Identification of Some DNA Damage-Inducible Genes of <i>Mycobacterium tuberculosis</i> : Apparent Lack of Correlation with LexA Binding," <i>Journal of Bacteriology</i> 183(15):4459-4467.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 282172002800	Application Number 10/773,618
		Applicant Thomas W. DUBENSKY, Jr. et al.	
		Filing Date February 6, 2004	Group Art Unit 1645
		Mailing Date January 6, 2005	

30.	Cole, R.S. (September 1971). "Inactivation of <i>Escherichia coli</i> , F' Episomes at Transfer, and Bacteriophage Lambda by Psoralen Plus 360-nm Light: Significance of Deoxyribonucleic Acid Cross-Links," <i>Journal of Bacteriology</i> 107(3):846-852.
31.	Cole, R.S. et al. (1975). "Repair of Cross-Linked DNA in <i>Escherichia coli</i> " Chapter 66 <u>In Basic Life Sciences: Molecular Mechanisms For Repair of DNA</u> Part B, Hollaender, A. ed. Plenum Press, pp 487-495.
32.	Dramsi, S. et al. (May 1997). "Identification of Four New Members of the Internalin Multigene Family of <i>Listeria monocytogenes</i> EGD," <i>Infection and Immunity</i> 65(5):1615-1625.
33.	Drevets, D.A. (July 1999). "Dissemination of <i>Listeria monocytogenes</i> by Infected Phagocytes," <i>Infection and Immunity</i> 67(7):3512-3517.
34.	Drevets, D.A. et al. (November 1995). " <i>Listeria monocytogenes</i> Infects Human Endothelial Cells by Two Distinct Mechanisms," <i>Infection and Immunity</i> 63(11):4268-4276.
35.	Dustoor, M.M. et al. (January 1979). "Antitumor Activity of <i>Listeria monocytogenes</i> on a Guinea Pig Fibrosarcoma," <i>Infection and Immunity</i> 23(1):54-60.
36.	Engelbrecht, F. et al. (1996). "A New PrfA-Regulated Gene of <i>Listeria monocytogenes</i> Encoding a Small, Secreted Protein Which Belongs to the Family of Internalins," <i>Molecular Microbiology</i> 21(4):823-837.
37.	Fong, L. et al. (March 15, 2001). "Dendritic Cells Injected Via Different Routes Induce Immunity in Cancer Patients," <i>Journal of Immunology</i> 166:4254-4259.
38.	Fong, L. et al. (November 2002). "Productive Infection of Plasmacytoid Dendritic Cells with Human Immunodeficiency Virus Type 1 Is Triggered by CD40 Ligation," <i>Journal of Virology</i> 76(21):11033-11041.
39.	Frankel, F.R. et al. (October 1994). "Delivery of HIV Antigens Using <i>Listeria monocytogenes</i> as a Live Vaccine Vector," <u>Abstracts of Papers Presented at the 1994 Meeting on Molecular Approaches to the Control of Infectious Diseases (October 5 - 9, 1994)</u> Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY pg. 56.
40.	Frankel, F.R. et al. (1995). "Induction of Cell-Mediated Immune Responses to Human Immunodeficiency Virus Type 1 Gag Protein by Using <i>Listeria monocytogenes</i> as a Live Vaccine Vector," <i>The Journal of Immunology</i> 155:4775-4782.
41.	Freitag, N.E. et al. (April 1999). "Examination of <i>Listeria monocytogenes</i> Intracellular Gene Expression by Using the Green Fluorescent Protein of <i>Aequorea victoria</i> ," <i>Infection and Immunity</i> 67(4):1844-1852.
42.	Gaillard, J-L. et al. (February 1996). "The <i>inlAB</i> Locus Mediates the Entry of <i>Listeria monocytogenes</i> into Hepatocytes In Vivo," <i>Journal of Experimental Medicine</i> 183(2):359-369.
43.	GenBank Accession No. AE017040 created on May 1, 2003, located at < http://www.ncbi.nlm.nih.gov > last visited on November 15, 2004, 159 pages.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 282172002800	Application Number 10/773,618
		Applicant	Thomas W. DUBENSKY, Jr. et al.
		Filing Date February 6, 2004	Group Art Unit 1645
		Mailing Date January 6, 2005	

	44.	GenBank Accession No. AL591824 created on July 18, 2002, located at <http://www.ncbi.nlm.nih.gov> last visited on November 15, 2004, two pages.
	45.	GenBank Accession No. AL591974 created on June 6, 2002, located at <http://www.ncbi.nlm.nih.gov> last visited on November 15, 2004, 87 pages.
	46.	GenBank Accession No. AL591975 created on June 6, 2002, located at <http://www.ncbi.nlm.nih.gov> last visited on November 15, 2004, 157 pages.
	47.	GenBank Accession No. M24199 created on October 22, 1993, located at <http://www.ncbi.nlm.nih.gov> last visited on November 15, 2004, three pages.
	48.	GenBank Accession No. M67471 created on April 26, 1993, located at <http://www.ncbi.nlm.nih.gov> last visited on November 15, 2004, four pages.
	49.	Giedlin, M.A. et al. (July 2003). "Therapeutic Immunization with Attenuated Recombinant <i>Listeria monocytogenes</i> Prolongs Survival in a Murine Transplant Model of Melanoma," (Abstract for the 94th Annual Meeting of the American Association for Cancer Research, Washington DC, USA, July 11-14, 2003) <i>Proceedings of the American Association For Cancer Research Annual Meeting</i> 44(2):167-168, Abstract No. 850.
	50.	Gouin, E. et al. (August 1994). "The Virulence Gene Cluster of <i>Listeria monocytogenes</i> Is Also Present in <i>Listeria ivanovii</i> , an Animal Pathogen, and <i>Listeria seeligeri</i> , a Nonpathogenic Species," <i>Infection and Immunity</i> 62(8):3550-3553.
	51.	Greiffenberg, L. et al. (December 1, 1997). " <i>Listeria monocytogenes</i> -infected Human Umbilical Vein Endothelial Cells: Internalin-Independent Invasion, Intracellular Growth, Movement, and Host Cell Responses," <i>FEMS Microbiology Letters</i> 157:163-170.
	52.	Greiffenberg, L. et al. (November 1998). "Interaction of <i>Listeria monocytogenes</i> with Human Brain Microvascular Endothelial Cells: In1B-Dependent Invasion, Long-Term Intracellular Growth, and Spread from Macrophages to Endothelial Cells," <i>Infection and Immunity</i> 66(11):5260-5267.
	53.	Hansen, M.T. (1982). "Sensitivity of <i>Escherichia coli acrA</i> Mutants to Psoralen Plus Near-Ultraviolet Radiation," <i>Mutation Research</i> 106:209-216.
	54.	Hartman, P.E. et al. (1996). "Breakthrough of Ultraviolet Light From Various Brands of Fluorescent Lamps: Lethal Effects on DNA Repair-Defective Bacteria," <i>Environmental and Molecular Mutagenesis</i> 27:306-313.
	55.	Higgins, D.E. et al. (1999). "Delivery of Protein to the Cytosol of Macrophages using <i>Escherichia coli</i> K-12," <i>Molecular Microbiology</i> 31(6):1631-1641.
	56.	Horton, R.M. et al. (1990). "Gene Splicing by Overlap Extension: Tailor-Made Genes Using the Polymerase Chain Reaction," <i>Biotechniques</i> 8(5):528-535.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
PTO/SB/08 (2-92) pa- 901676	Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 282172002800	Application Number 10/773,618
		Applicant	Thomas W. DUBENSKY, Jr. et al.
		Filing Date February 6, 2004	Group Art Unit 1645
		Mailing Date January 6, 2005	

	57.	Ikonomidis, G. et al. (1994). "Delivery of a Viral Antigen to the Class I Pathway by <i>Listeria monocytogenes</i> : A Potential Vaccine Vector," <i>Abstracts of the 94th General Meeting of the American Society For Microbiology</i> (May 23-27, 1994) Las Vegas Convention Center: Las Vegas, NV pg. 159, Abstract No. E-90.
	58.	Ikonomidis, G. et al. (December 1994). "Delivery of a Viral Antigen to the Class I Processing and Presentation Pathway by <i>Listeria monocytogenes</i> ," <i>J. Exp. Med.</i> 180:2209-2218.
	59.	International Search Report mailed December 7, 2004, for PCT/US2004/003429 filed February 6, 2004, 11 pages.
	60.	Jones, S. et al. (December 1994). "Characterization of <i>Listeria monocytogenes</i> Pathogenesis in a Strain Expressing Perfringolysin O in Place of Listeriolysin O," <i>Infection and Immunity</i> 62(12):5608-5613.
	61.	Kim, J.J. et al. (April 2001). "Construction and Analysis of Photolyase Mutants of <i>Pseudomonas aeruginosa</i> and <i>Pseudomonas syringae</i> : Contribution of Photoreactivation, Nucleotide Excision Repair, and Mutagenic DNA Repair to Cell Survival and Mutability following Exposure to UV-B Radiation," <i>Applied and Environmental Microbiology</i> 67(4):1405-1411.
	62.	Lecuit, M. et al. (June 1, 2001). "A Transgenic Model for Listeriosis: Role of Internalin in Crossing the Intestinal Barrier," <i>Science</i> 292:1722-1725.
	63.	Lin, L. et al. (April 1997). "Photochemical Inactivation of Viruses and Bacteria in Platelet Concentrates by Use of a Novel Psoralen and Long-Wavelength Ultraviolet Light," <i>Transfusion</i> 37(4):423-435.
	64.	Mandl, S. et al. (July 1998). "Poliovirus Vaccine Vectors Elicit Antigen-Specific Cytotoxic T Cells and Protect Mice Against Lethal Challenge with Malignant Melanoma Cells Expressing a Model Antigen," <i>Proc. Natl. Acad. Sci. USA</i> 95:8216-8221.
	65.	Pan, Z-K. et al. (May 1995). "A Recombinant <i>Listeria monocytogenes</i> Vaccine Expressing a Model Tumour Antigen Protects Mice Against Lethal Tumour Cell Challenge and Causes Regression of Established Tumours," <i>Nature Medicine</i> 1(5):471-477.
	66.	Pan, Z-K. et al. (November 1, 1995). "Regression of Established Tumors in Mice Mediated by the Oral Administration of a Recombinant <i>Listeria monocytogenes</i> Vaccine," <i>Cancer Research</i> 55:4776-4779.
	67.	Parida, S.K. et al. (April 1998). "Internalin B is Essential for Adhesion and Mediates the Invasion of <i>Listeria monocytogenes</i> into Human Endothelial Cells," <i>Molecular Microbiology</i> 28(1):81-93.
	68.	Peters, C. et al. (January 2003). "Tailoring Host Immune Responses to <i>Listeria</i> by Manipulation of Virulence Genes - The Interface Between Innate and Acquired Immunity," <i>FEMS Immunology and Medical Microbiology</i> 35:243-253.
	69.	Sander, P. et al. (June 2001). " <i>Mycobacterium bovis</i> BCG <i>recA</i> Deletion Mutant Shows Increased Susceptibility to DNA-Damaging Agents but Wild-Type Survival in a Mouse Infection Model," <i>Infection and Immunity</i> 69(6):3562-3568.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 282172002800	Application Number 10/773,618
		Applicant	Thomas W. DUBENSKY, Jr. et al.
		Filing Date February 6, 2004	Group Art Unit 1645
		Mailing Date January 6, 2005	

70.	Sanderson, S. et al. (1994). "LacZ Inducible, Antigen/MHC-Specific T Cell Hybrids," <i>International Immunology</i> 6(3):369-376.
71.	Sawyer, R.T. et al. (November 1996). "Internalin A Can Mediate Phagocytosis of <i>Listeria monocytogenes</i> by Mouse Macrophage Cell Lines," <i>Journal of Leukocyte Biology</i> 60:603-610.
72.	Shen, Z. et al. (1997). "Cloned Dendritic Cells Can Present Exogenous Antigens on Both MHC Class I and Class II Molecules," <i>Journal of Immunology</i> 158:2723-2730.
73.	Shimizu, K. et al. (March 15, 2001). "Enhancement of Tumor Lysate- and Peptide-pulsed Dendritic Cell-based Vaccines by the Addition of Foreign Helper Protein," <i>Cancer Research</i> 61:2618-2624.
74.	Simon, R. et al. (November 1983). "A Broad Host Range Mobilization System for <i>In Vivo</i> Genetic Engineering: Transposon Mutagenesis in Gram Negative Bacteria," <i>Bio/Technology</i> pp. 784-791.
75.	Sinden, R.R. et al. (November 1978). "Repair of Cross-Linked DNA and Survival of <i>Escherichia coli</i> Treated with Psoralen and Light: Effects of Mutations Influencing Genetic Recombination and DNA Metabolism," <i>Journal of Bacteriology</i> 136(2):538-547.
76.	Smith, K. et al. (1992). "Use of a New Integrational Vector to Investigate Compartment-Specific Expression of the <i>Bacillus subtilis</i> <i>spoIIIM</i> Gene," <i>Biochimie</i> 74:705-711.
77.	Starks, H. et al. (July 1, 2004). " <i>Listeria Monocytogenes</i> as a Vaccine Vector: Virulence Attenuation or Existing Antivector Immunity Does Not Diminish Therapeutic Efficacy," <i>Journal of Immunology</i> 173:420-427.
78.	Suárez, M. et al. (December 2001). "A Role For ActA in Epithelial Cell Invasion by <i>Listeria monocytogenes</i> ," <i>Cellular Microbiology</i> 3(12):853-864.
79.	Uchijima, M. et al. (1998). "Optimization of Codon Usage of Plasmid DNA Vaccine Is Required for the Effective MHC Class I-Restricted T Cell Responses Against an Intracellular Bacterium," <i>Journal of Immunology</i> 161:5594-5599.
80.	Vazquez-Boland, J-A. et al. (January 1992). "Nucleotide Sequence of the Lecithinase Operon of <i>Listeria monocytogenes</i> and Possible Role of Lecithinase in Cell-to-Cell Spread," <i>Infection and Immunity</i> 60(1):219-230.
81.	Weiskirch, L.M. et al. (1997). " <i>Listeria monocytogenes</i> : A Potent Vaccine Vector for Neoplastic and Infectious Disease," <i>Immunological Reviews</i> 158:159-169.
82.	Zhukov-Verezhnikov, N.N. et al. (1981). "Antigens Common to Human Malignant Tumors and Certain Species of Microorganisms," <i>Bulletin of Exp. Biol. Med.</i> 92:1234-1237.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
PTO/SB/ 08 (2-92) pa- 901676	Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE